Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 5,830 shares at $37.75 ($220K) on 2024-02-15, disclosed to the SEC on 2024-02-20.
Scheduled sale ($220k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.75 | 2,915 | $110K | 50.0% |
| 2 | $37.75 | 2,915 | $110K | 50.0% |
| Total | $37.75 avg | 5,830 | $220K | 100% |
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |